Congnos Therapeutics
Unlocking the Future of Therapeutic Health
Discover a transformative therapeutic platform that reshapes the current standard of neurological and oncological care – a step towards a healthier, happier lifestyle.
Cognos Mission
Leading the convergence of science, data, and technology utilizing AI and Blockchain
At Cognos Therapeutics, our mission is to develop and commercialize medical products that combine diagnostic, therapeutic, and sensing technologies with state-of-the-art drug delivery to advance healthcare through improved patient outcomes.
A Novel and Ground-Breaking Advancement
SINNAIS™ Implantable Smart Pump
Our innovative SINNAIS™ implantable pump represents a platform designed for the future, utilizing the power of AI, blockchain and cloud connectivity and incorporating microprocessor, microelectronics, communication capabilities, and embedded programmable parameters in its architecture. Focusing on targeted, controlled delivery of therapeutics to the brain, a departure from the current standard of intraventricular drug delivery.
This proprietary, state-of-the-art piezoelectric micropump can deliver precise 1 µL doses according to a preprogrammed schedule, achieving 10 times greater accuracy in drug delivery compared to current implantable pumps on the market.
Target indications
Serving Unmet Needs
$360B
U.S. Alzheimer's Economic Cost
Cognos is at the forefront of developing innovative treatments addressing Alzheimer’s and various types of cancer. Alzheimer’s disease, affecting over 50 million people globally, including 6.9 million in the U.S., represents a significant challenge due to the difficulty of drug delivery to the brain and the economic burden of $360 billion annually.
50M
Global Patient Base
The company’s brain microdialysis technology is positioned to enable the first streamlined treatment for Alzheimer’s, overcoming the blood-brain barrier and creating substantial potential for market leadership. In addition to Alzheimer’s, Cognos is tackling unmet needs in the treatment of central nervous system (CNS) diseases and multiple neurological cancers, including Leptomeningeal carcinomatosis (LC), glioblastoma (GBM), and pancreatic cancer. The SINNAIS™ AI smart drug delivery implantable pump is designed to address these critical areas.
The total U.S. addressable market for SINNAIS™ is at least 180,000 patient cases per year, based on estimated annual diagnoses of 110,000 for LC, 60,000 for pancreatic cancer, and 12,000 for glioblastoma. LC cases associated with breast cancer, melanoma, and lung cancer comprise over 50% of the target population.
The combined treatment market for these cancer diagnoses in the U.S. is estimated to be approximately $15.8 billion per year, including $6 billion for LC, $8 billion for pancreatic cancer, and $1.8 billion for glioblastoma. With this multi-faceted approach, Cognos is poised to capture significant opportunities and address critical gaps in both neurodegenerative and cancer treatment markets.
$360B
U.S. Alzheimer's Economic Cost
50M
Global Patient Base